Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOJOURN vs LARIN 1.5/30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
FDA-approved for fibromyalgia,Off-label uses include chronic low back pain, osteoarthritis pain, diabetic peripheral neuropathy
Prevention of pregnancy
400 mg orally once daily
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Metabolized by CYP2D6 and CYP3A4; major metabolites are desmethyl and N-desisopropyl derivatives. Inhibits CYP2D6.
Ethinyl estradiol: primarily CYP3A4; norethindrone: primarily CYP3A4, with some reduction to active metabolites.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
88% bound to serum albumin; minor binding to alpha-1-acid glycoprotein.
Ethinyl estradiol: 97-98% bound to albumin; Norethindrone: 93-99% bound to SHBG and albumin.
0.8 L/kg; indicates distribution into total body water.
Ethinyl estradiol: 2.5-5 L/kg; Norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Oral: 65% due to first-pass metabolism; IM: 90%; rectal: 50%.
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~50-60% (first-pass metabolism).
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg once daily; GFR <30 m L/min: 100 mg once daily; hemodialysis: 100 mg after each dialysis session
No dose adjustment required in mild to moderate renal impairment (Cr Cl >=30 m L/min). Use contraindicated in severe renal impairment (Cr Cl <30 m L/min) or renal failure due to potential for fluid retention and hyperkalemia.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: contraindicated
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, lowest possible effective dose should be used with close monitoring of liver function.
Weight ≥40 kg: 400 mg once daily; Weight 20-39 kg: 200 mg once daily; Weight <20 kg: 100 mg once daily
Post-menarche adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). Safety and efficacy in pre-menarche girls have not been established.
Start at 200 mg once daily; titrate based on renal function and tolerability
Not indicated for postmenopausal women. No specific geriatric dose adjustments; however, consider increased risk of thromboembolic events and cardiovascular disease in women aged >40 years who smoke or have other risk factors.
Suicidality: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor for worsening and emergence of suicidal thoughts and behaviors.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome (especially when co-administered with other serotonergic drugs), severe hypertension (especially in patients with underlying hypertension), hepatic injury (elevated transaminases), acute angle-closure glaucoma, seizures (lowered threshold), hyponatremia (particularly in elderly), and withdrawal symptoms upon abrupt discontinuation (e.g., dizziness, nausea, headache).
Cardiovascular disease risk: smoking, hypertension, diabetes, hyperlipidemia,Thromboembolic events: increased risk in surgery, postpartum, or immobilization,Liver disease: discontinue if jaundice develops,Gallbladder disease: increased risk,Glucose intolerance: monitor in diabetics,Blood pressure elevation: monitor periodically,Depression: discontinue if severe
Hypersensitivity to drug or any component; concurrent use of MAOIs (within 14 days) or other serotonergic drugs (risk of serotonin syndrome); severe hepatic impairment; uncontrolled hypertension; recent myocardial infarction or unstable coronary artery disease.
Current or history of venous thromboembolism,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Known or suspected pregnancy,Liver tumors or active liver disease,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component,Cigarette smoking in women over 35
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit tyramine-rich foods (aged cheeses, cured meats) due to possible MAOI activity. Take with food if gastrointestinal upset occurs.
Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. No specific dietary restrictions; can be taken with or without food.
First trimester: Increased risk of major congenital malformations (cardiovascular, neural tube defects) based on animal studies and limited human data. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and preterm birth.
First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters: Associated with adverse fetal outcomes including low birth weight, preterm delivery, and neonatal withdrawal symptoms. Avoid use during pregnancy due to known risks.
Excreted into breast milk; M/P ratio 0.8. Contraindicated due to potential neonatal toxicity. Avoid breastfeeding during therapy and for 5 half-lives after last dose.
Small amounts of ethinyl estradiol and norethindrone transfer into breast milk, with a milk-to-plasma ratio approximately 0.2-0.3 for norethindrone and <0.1 for ethinyl estradiol. May reduce milk production and composition. Use caution and consider alternative contraception in nursing mothers.
Dose increase of 30% recommended in second and third trimesters due to increased clearance. Monitor trough concentrations and adjust to maintain therapeutic range (0.5–1.0 mcg/m L).
Contraindicated in pregnancy; no dose adjustment is applicable as the drug should be discontinued immediately upon confirmed pregnancy.
SOJOURN is a fictional drug; no clinical data exists. Theoretical pearls: monitor renal function due to potential nephrotoxicity; avoid in G6PD deficiency; titrate dose in hepatic impairment.
Larin 1.5/30 is a monophasic combination oral contraceptive containing 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. It is indicated for prevention of pregnancy and may also be used for management of acne and menstrual disorders. Advise patients to take at the same time daily to maintain consistent hormone levels. Counsel about breakthrough bleeding, especially during first cycles. Monitor for thrombotic events; use with caution in women with migraine with aura, hypertension, or smoking history over age 35. Effectiveness may be reduced with strong CYP3A4 inducers. Consider alternative contraception if patient is on chronic enzyme-inducing drugs. Use of NSAIDs can increase risk of breakthrough bleeding. Not recommended during breastfeeding or pregnancy.
Take exactly as prescribed; do not double doses.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Avoid alcohol while taking SOJOURN.,Complete the full course even if symptoms improve.,Use adequate contraception if of childbearing potential.
Take one tablet at the same time each day, with or without food.,If you miss a dose, follow the instructions in the package insert; use backup contraception if needed.,Common side effects include nausea, breast tenderness, headache, and breakthrough bleeding, especially in the first few months.,Seek medical attention if you experience leg pain, chest pain, shortness of breath, severe headache, vision changes, or jaundice.,Do not smoke while taking this medication as it increases the risk of serious cardiovascular side effects.,Inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.,This medication does not protect against sexually transmitted infections; use condoms for STI prevention.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOJOURN vs LARIN 1.5/30, answered by our medical review team.
SOJOURN is a Combination Oral Contraceptive that works by Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.. LARIN 1.5/30 is a Combination Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOJOURN and LARIN 1.5/30 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOJOURN is: 400 mg orally once daily. The standard adult dose of LARIN 1.5/30 is: One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOJOURN and LARIN 1.5/30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOJOURN is classified as Category C. First trimester: Increased risk of major congenital malformations (cardiovascular, neural tube defects) based on animal studies and limited human data. Second and third trimesters:. LARIN 1.5/30 is classified as Category C. First trimester: No consistent evidence of major malformations, but a small increased risk of cardiovascular defects and oral clefts cannot be excluded. Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.